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INTRODUCTION
The United States is currently in the throes of a large scale, social
movement that many commentators deem a "food revolution," 2 but
might more aptly be termed a food re-evolution. Open any current
food magazine or watch any television show pertaining to food and,
odds are, it is brimming with dozens of references to the allure of the
farmer's market, the benefits of buying locally sourced foods, ideas
about how to create a menu centered around seasonal fruits and
vegetables, reasons to use fewer ingredients and emphasize whole,
organically grown foods - the list goes on and on. Rather than
encouraging advances in the field of biotechnology for food
production, consumers are consistently, and adamantly, demanding a
return to the days when food was simple and unprocessed, grown in
their communities by farmers they know, and not altered, chemically
or otherwise. 3 Moreover, consumers are thirsting for access to
Associate Professor of Law at Vermont Law School in South Royalton, Vermont.
She is beyond thankful to her partner and soon to be husband, Ben Jervey, for his
never wavering support, guidance, and patience.
2. Why We Need a Food Revolution, JAMIE OLIVER's FOOD REVOLUTION,

http://www.jaiieoliver.com/us/foundation/jamies-food-revolution/why (last visited
Nov. 13, 2011) (The term "food revolution" can be attributed, in part, to Jamie
Oliver, the activist chef attempting to improve the health of our youth.).
3. See

e.g.,

Good,

Clean,

Fair,

SLOW

FOOD

USA,

http://xxwww.slowfoodusa.org/index.php/slow food/good clean fair/ (last visited
Nov. 13, 2011) ("Slow Food USA advocates for food and farming policy that is
good for the public, good for fanmers and Workers, and good for the planet."); Mary
Burros, Obanas to Plant Vegetable Garden at White House, N.Y. Times, March
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increased information about the life cycles of the food they consume.
The reasons for this re-evolution are many: rational fears about future
and yet unknown effects of biotechnology coexist with concerns over
animal health, safety, and welfare, creating a justifiable concern that
policy decisions about our food supply will soon result in serious,
perhaps irreversible, harm to the natural and human environent.
These issues are increasingly brought to bear in the public eye as
advocacy groups, food producers, doctors, and others challenge both
the use of biotechnology in food production, and the Food and Drug
Administration (FDA)'s unwillingness to require any special labeling
thereof.4 In the realm of milk and dairy products, the fight over the
use of the artificial growth honnone, recombinant Bovine
Somatotropin ("rBST") has raged publicly since the early 1990s
when the FDA approved Monsanto's controversial application for
Posilac'C, their version of rBST, finding there was no significant
compositional difference between milk from cows treated with the
drug and those that were not.5
Since that time, the courts have considered numerous challenges to
both the approval of rBST, and the labeling of products from cows
treated with it. In September 2010, the Sixth Circuit Court of
Appeals upheld the constitutionality under the First Amendment of a
dairy producer's right to include a label stating the milk was "rBST
free," finding the language was not misleading due to evidence
proving the real, compositional difference between milk from cows

19, 2009,
at Al,
available at http://www.nytimes.com/2009/03/20/
dining/20garden.htil (discussing the Obamas' organic vegetable garden at the
White House to symbolize "that growing more food locally, and organically, can
lead to more healthful eating and reduce reliance on huge industrial farms that use
more oil for transportation and chemicals for fertilizer"); Nestle, Marion, Jhat to
Eat (2007); Pollan, Michael, In Defense ofFood(2008).
4. See Interim Guidance on the Voluntary Labeling of Milk and Milk Products
from Cows that Have Not Been Treated with Recombinant Bovine Somatotropin,
59 Fed. Reg. 6279, 6280 (Feb. 10, 1994) ("[T]he agency found that there was no
significant difference between milk from treated and untreated cows and, therefore,
concluded that under the Federal Food, Drug, and Cosmetic Act (the act), the
agency did not have the authority in this situation to require special labeling for
milk from rbST-treated cows").
5. See id.

104

FORDHAM ENVRONMENTAL LAW REVIEW

[VOL. 23.1

treated with rBST and milk from cows that were not. 6 This article
proposes that the Boggs decision provides a framework for the
argument that, despite its position to the contrary, the FDA can and
should require mandatory disclosures on milk that comes from cows
treated with rBST as the first step in returning to a time when
consumers were provided with greater access to infornation about
the foods they consume. Given the recognized compositional
difference in the two types of milk, the agency's failure to do so
makes any label without such disclosures misleading under the Food,
Drug and Cosmetic Act.
Part I of this article provides a brief history of the FDA's authority
under the Food, Drug, and Cosmetic Act, as well as the Act's
purposes with respect to labeling, and briefly considers the agency's
interpretation of that grant of authority. Part II of the article discusses
the FDA's approval of rBST and the resulting challenge to that
decision. In Part III, the article provides an overview of the First
Amendment
litigation challenging
dairy producers'
and
manufacturers' ability to include statements about rBST on the labels
of their products. Finally, Part IV demonstrates how the recent
decision in InternationalDairy Foods Association v. Boggs7 may be

instrumental in requiring the FDA to mandate labeling of milk from
cows treated with rBST due to the court's acknowledgement of the
compositional difference between conventional and rBST-free milk.
I.

HISTORY OF THE STATUTORY GRANT OF AUTHORITY TO
REGULATE FOOD PRODUCTS

A.

The Pure Foods andDrugs Act of 1906

The Food and Drug Administration is the self-proclaimed "oldest
comprehensive consumer protection agency in the U. S. federal
goovernment."8 Initially, the agency was formed as part of the Bureau
of Chemistry,9 but first came into existence in its modern day
6. International Dairy Foods Association v. Boggs, 622 F.3d 628 (6th Cir.
2010).
7. Id.
8. Food and Drug Adninistration History, FDA.GOV, http://www.fda.gov/

AboutFDA/WhatWeDo/Historv/default.htm (last visited Nov. 13, 2011).
9. See Records of the Bureau of Agricultural and Industrial Chemistry,
NATIONAL ARCHIVES, http://vww.archives.gov/research/guide-fed-records/ groups/
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incarnation with the passage of the Federal Foods and Drugs Act,
which created the agency's regulatory functions.' 0 After many
unsuccessful attempts 1 ' at passing uniform federal legislation
directed at addressing the increasingly disconcerting issues of food
safety and adulteration in the late 1800s, President Theodore
Roosevelt finally signed the law into effect in 1906.12 The major
purpose of the law was to prevent the adulteration of food, leading
many representatives from agricultural states to lend tremendous
support to its passage.13 The law created and defined very specific
standards with regard to drugs. However, the law did not create
corresponding requirements for food products, though it did "prohibit
the addition of any ingredients that would substitute for the food,
conceal damage, pose a health hazard, or constitute a filthy or
decomposed substance."' 4
In the early years, the agency's main emphasis was the regulation
of food rather than drugs. Harvey W. Wiley, the agency's chief
administrator, appointed in 1883, was a chemist and longtime
champion of pure foods, and found that foods posed a greater risk to
human health than drugs as most chemical additives were
097.html (last visited Nov. 13., 2011) (outlining the bureau's administrative history
as established in the Agricultural Research Administration (ARA), February 14,
1943, by ARA Memorandum 5, February 13, 1943, pursuant to EO 9069, February
23, 1942., and Secretary of Agriculture's Memorandums 960, December 14, 1941
and 986, February 25., 1942).
10. John P. Swann, Ph.D., FDA 's Origin., FDA.GOV, http://vww.fda.gov/
AboutFDA/WhatWeDo/History/Origin/ucml24403.htin (last visited Sept. 1, 2011)
(adapted from A HISTORICAL GUIDE TO THE U.S. GOVERNMENT, (George Kurian,

ed., Oxford University Press 1998)).
11. See Charles Wesley Dunn, OriginalFederal Food, and Drugs Act of 1906,
As Amended: Its Legislative History, I FOOD DRUG COSM. L.Q. 297 (1946) (prior

to the passage of the Act, 103 bills were introduced to Congress).
12. John P. Swann, FDA History - Part 1, FDA.GOV, http://www.fda.gov/
AboutFDA/WhatWeDo/History/Origin/ucm054819.htm (last visited Nov. 12,
2011) (adapted from A HISTORICAL GUIDE TO THE U.S. GOVERNMENT, (George

Kurian, ed., Oxford University Press 1998)).
13. Wesley, supra note 10 at 303 ("These leaders in Congress for a national
food and drug law . .. principally came from agricultural states; and to record the

fact that representatives of agriculture were foremost advocates of this law, because
they were deeply concerned that agricultural products sold to the consuming public
should be pure., wholesome and honest.").
14. Id.
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"unnecessary adulterants." 1 5 Moreover, Wiley placed great emphasis
on the truthfulness of food labeling, even when the wholesomeness
of the product was not at issue. 16 Under the auspices of the agency,
Wiley conducted a series of experiments to test his theories about the
dangers of specific food additives and preservatives frequently used
in the early 1900s.
He assembled a group of young men, whom
journalists covering the trials called the "Poison Squad," and fed
them meals composed of the best quality ingredients prepared "in the
most appetizing and hygienic fashion" 8 that were also laced with
measured amounts of common preservatives and additives.' 9
All of the men in the study demonstrated ill effects as a result of
their participation, which led Wiley to conclude that "the effect of
food preservatives upon on the system was...mildly injurious or
deadly, according to the amount and character of the preservatives
absorbed." 20 The Poison Squad experiments greatly influenced
Wiley's opinions about the need for strict regulation of chemical
additives and preservatives in food products, and led to his heavy
emphasis on this issue during his tenure as the chief administrator. 21
15. Id.

16. Anderson, Oscar E. Jr., Pure-Food Issue: A Republican Dilemma, 19061912, Food, Drug, Cosmetic Law Journal, Vol. 12 , Issue 1, 34 (January 1957)
(Upon Wiley's urging, Wilson signed Food Inspection Decision 45, which ruled
that "mixtures of bourbon whiskv and blended spirits (ethyl alcohol) were not to be
labeled "blended whisky" because blends were to be a mixture of like spirits. In
Wiley's opinion, the addition of neutral spirits created an imitation. The issue was
not about the "wholesomeness" of the resulting product, but rather "a matter of
honesty.").

17. Janssen, Wallace F., The Story of the Laws Behind the Labels, FDA.GoV,
http://vww.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm056044.htin
(last visited October 13, 2011); Peter Barton Hutt & Peter Barton Hutt II, A History
of Government Regulation of Adulteration and Misbranding of Food, 39 Food,
Drug, Cosmetic L.J. 2 (1984) ("Congress specifically appropriated funds in 1900
'to investigate the character of proposed food preservatives and coloring matters; to
determine their relation to digestion and health; and to establish the principles
which should guid their use.").
18. Poison Squad Escapes FederalFood Experts, N.Y. TIMES, May 22, 1904,
http://query.nytimes.com/men/archivefree pdf?res=FI0714F8355FI3 718DDDABOA94DD405B848CFID3 (last visited
January 1, 2012).
19. Id.

20. Id.
21. Swann, supra note 10.
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On this point, however, Wiley's views diverged with the President
and then Secretary of Agriculture, James Wilson, who favored
scientific advances in the field, were sympathetic to industry, and less
vehement about the purity of the country's food supply.22 This
difference of opinion between Wiley and the Administration, in
addition to resistance by the Administration to defend Wiley's strong
positions, ultimately led to Wiley's resignation from the agency in
1912.23
1. The Food and Drugs Act in the Courts
One of the early cases decided after the passage of the Act
demonstrates both the Supreme Court's willingness to recognize a
broad grant of authority to the agency, as well as the agency's
aggressive approach in interpreting the requirements under the new
statute with respect to misbranding. In US. v. Antikamnia Chemical
Company,2 4 the Court considered a challenge under the Federal
Foods and Drug Act to the government's requirement that a drug's
label include not only its ingredients, but also any derivatives. 25 In
response to the argument that the agency was overstepping its
statutory grant of authority by creating stricter requirements than
those Congress had authorized under the law, the Court stated, "the

purpose of the act is to secure the purity of food and drugs, and to
inform purchasers of what they are buying. Its provisions are directed
to that purpose and must be construed to effect it." 26 Ultimately, the
Court found the agency's requirements for greater disclosures in
labeling did not create a significant burden for the manufacturers or
producers, as they were fully aware of the ingredients included in
their products, and greater disclosure was in the best interest of the
public health.27

22. Hutt, supra note 17, at 56-57; Anderson, supra note 16, at 45 (Members of

the Administration wanted to bring cases against producers that could actually be
won and did not share Wiley's passion for "the militant, even radical,
administration of the law in the interest of the consumer."). .
23. Id
24. United States v. Anitikamnia Chemical Co., 231 U.S. 654, 665 (1914).
25. Id
26. Id
27. Id
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A decade later, the Court considered a misbranding case involving
a product labeled and marketed as apple cider vinegar made from
dehydrated apples that, during the manufacturing process, were
rehydrated with water in substantially the same amount as that
removed in the dehydration process.2 8 While the product contained
very small amounts of barium from the manufacturing process, the
government did not allege that this substance was injurious to or
presented a threat to public health. 29 Additionally, none of the parties
suggested that the cider produced was of inferior quality or taste,
although the district judge did note a slight difference in both taste
and appearance. 30 The Court ultimately found that even though the
resulting product was similar to apple cider vinegar made from fresh
apples, the addition of water during the manufacturing process
created a different product entirely, causing the product to be
misbranded as it was not "the identical thing that the brand indicates
it to be."3 1 Therefore, while the statements on the label were
technically correct, the Court found them misleading to consumers.32
Interestingly, the Court noted that its holding with respect to
misbranding was not based on the differences in production or
manufacture between the two products, as the law did not require
disclosures regarding those processes.33 Rather, its decision was
based on the fact that the substance marketed and labeled as apple
cider vinegar was not, in fact, apple cider vinegar because of its
compositional difference in substance and ingredients.34
In each of these cases, the Court demonstrated an unwillingness to
permit manufacturers and producers from misleading consumers by
purporting to sell a product that was not exactly what it said it was or
failing to fully disclose specific ingredients. The Court based its
decisions on the express language of the Federal Food and Drugs
Act, as well as the clear congressional intent to both protect the
purity and safety of food and fully inform consumers about the
28. United States v. Ninety-Five Barrels More or Less Alleged Apple Cider
Vinegar, 265 U.S. 438 (1924).
29. Id at 441.
30. Id at 443.
31. Id at 444.

32. Id
33. Id at 445.
34. Id
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products they were purchasing. 35 Part of the motive behind this
approach was to prevent economic harm to consumers by adopting a
low tolerance for inferior food products labeled in the same maimer
as their superior or more "wholesome" counterparts.36 However,
these laudable goals to protect and inform consumers coexisted with
govennmental support for technological advances in increasing the
life cycles of food and enhancing flavor.37
The Court decided other cases during the same period that
evidenced the support for scientific and technological advances in
food production and the limits on the FDA's power. In contrast to the
FDA's broader authority in the misbranding cases,38 the Court held
that the Act did not permit the agency to seize 625 bags of allegedly
adulterated flour that had been treated with a chemical additive
unless the agency could demonstrate that the additive may "render
such article injurious to health." 39 Relying again on the plain
35. Id. at 442-43.
36. Pure Food and Drugs Act 8., Pub. L. No. 59-384, 34 Stat. 768 (1906)
(current version at 21 U.S.C. § 341(1938)) (Language of the current statute
explicitly references the Secretary's goals of promoting "honesty and fair dealing
in the interest of consumers" with respect to labeling requirements.).
37. See Pure Food and Drugs Act at § 8 (permitting manufacturers to add
"poisonous" or "deleterious" ingredients). See also Dunn, supra note 11, at 305
("In thus speaking of the need for a national food and drug law, we should go on to
say that during the quarter of a century when the 1906 act was legislatively
developed., our country was emerging from a rural into an industrial nation; the
food and drug industries were beginning to be organized on the basis of mass
production and distribution: the science of food and drug manufacture had reached
the point where it could be constructively used to improve these products or
destructively used to debase them; and the uncontrolled forces of competition were
working for the sophistication of these products, in order to secure the commercial
advantage of a lower price. All of which means that the inherent need for the law of
this act was then progressively increased by the evolution in the food and drug
order and a working of the forces underlying its competitive operation.").
38. See Pure Food and Drugs Act at § 7.
39. United States v. Lexington Mill & Elevator Co., 232 U.S. 399, 409 (1914)
("The statute upon its face shows that the primary purpose of Congress was to
prevent injury to the public health by the sale and transportation in interstate
commerce of misbranded and adulterated foods. The legislation, as against
misbranding. intended to make it possible that the consumer should know that an
article purchased was what it purported to be; that it might be bought for what it
really was, and not upon misrepresentations as to character and quality. As against
adulteration, the statute was intended to protect the public health from possible
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language of the statute, the Court found that Congress was clear in its
directive regarding chemical additives, and specifically included
language that intended to allow producers and manufacturers to
include "poisonous or other added deleterious ingredient[s]" 40 to their
products so long as they were not injurious to the public health. 4 In
that case, the Court cited legislative history to demonstrate that
Congress did not intend to grant the agency the authority to regulate
any product that might contain poison in the form of chemical
additives. 42 The Lexington Mill decision left room for the argument
that the agency retained a broad grant of authority to regulate where
it was able to demonstrate that the additive had the potential to result
in some injurious effect rather than requiring a showing that the
additive actually did cause some sort of injury to health.4

However,

the legislative support for making a claim that a product was
adulterated due to the addition of a chemical additive in all instances
where a producer or manufacturer used what the agency deemed a
poison in the manufacturing process did not exist. 44 Consequently,
even in these early years when the purposes of the Act were to
protect human health and the purity of foods, Congress' apparent
willingness to permit chemical additives in food products where the
agency sought to prevent them demonstrated the broad support for

injury by adding to articles of food consumption poisonous and deleterious
substances which might render such articles injurious to the health of consumers.").
40. Id at 410.
41. Id at 411 ("If it cannot by any possibility, when the facts are reasonably
considered, injure the health of any consumer, such flour, though having a small
addition of poisonous or deleterious ingredients., may not be condemned under the
act.").
42. Id at 411-12 ("[A]lthough it may be said in passing that the meaning which
we have given to the statute was well expressed by Mr. Heyburn., chairman of the
committee having it in charge upon the floor of the Senate (Congressional Record,
vol. 40, pt. 2, p. 1131): 'As to the use of the term 'poisonous,' let me state that
everything which contains poison is not poison. It depends on the quantity and the
combination. A very large majority of the things consumed by the human family
contain, under analysis, some kind of poison, but it depends upon the combination,
the chemical relation which it bears to the body in which it exists, as to whether or
not it is dangerous to take into the human system.").
43. Id at 411.
44. Idat 410-11.
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what were then considered advances in food production, which has
endured for many decades.4 5
B.

The FederalFood,Drug and Cosmetic Act of 193846

While the Food and Drugs Act of 1906 persisted for many years,
mounting concerns over the limited authority of the agency, the Act's
inability to address unregulated and emerging risks with respect to
food and drug safety, and the expanding field of cosmetics led to the
drafting of the Food, Drug and Cosmetic Act of 1938.47 The 1938
Act was much stronger in the sense that it gave the agency greater
enforcement authority as well as the ability to set standards for the
identity and quality of food products.48 This was a critical addition
because it created enforceable, legal standards that the government
could use in misbranding and adulteration cases. 49 Additionally, the
FDCA did not appear to interfere with the states' continued ability to
regulate food products within their borders, even where those laws
might have affected interstate commerce except for those situations
where the laws conflicted or where Congress created a system of
"thorough regulation"o for a specific product.
Congress has not amended the 1906 Act's misbranding provisions
since passage of the 1938 Act, and they largely reflect the same
principles, if not similar language, of the provisions included in the
1906 Act.52 The courts considering misbranding cases under the
revised Act followed the Court's reasoning in the Ninety-Five
Barrels case, holding that labels including disclaimers regarding
misleading statements did not cure the misbranding 5 3 as the court's
review would consider the pennissibility of the language in light of
45. Id
46. 21 U.S.C. 301 et seq.
47. 1917 REPORT OF THE USDA.

BUREAU OF CHEMISTRY,

reprinted in MERRIL

ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 11-12 (3d ed. 2007).

48. See Developments in the Law: The Federal, Food, Drug, and Cosmetic Act,
67 HARV. L. REV. 632, 636 (1954).
49. See id.
50. Id
51. Id

52. Pure Food and Drugs Act § 8, Pub. L. No. 59-384, 34 Stat. 768 (1906)
(current version at 21 U.S.C. § 341(1938)).
53. Id at 653 (citing Pasadena Research Laboratories, Inc. v. United States, 169
F.2d 375, 383 (9th Cir.), cert. denied, 335 U.S. 853 (1948)).
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"the probable inference a consumer might draw from it."54
Moreover, the Supreme Court held that the amended Act was
Congress' attempt to further strengthen its ability to regulate and
control harmful food and drugs in commerce.55 The Court found that
Congress specifically intended that the Act "touch phases of the lives
and health of people which, in the circumstances of modern
industrialism, are largely beyond self-protection."5 6 Commentators
have opined that these cases set the tone for an era of deference to
proactive agency decisions intended to further the goals of the
statute.
1. The Agency's Interpretations of the Act
The current FDA generally follows the same logic in the sense that
the agency remains concerned about product misbranding and the
potential for consumer confusion.5 However, rather than regulating
food products to increase the availability of information for
consumers, the FDA now takes the approach that information
regarding the absence of certain additives or indicating a different
process that does not include drugs or additives is misleading to
consumers because it suggests a superior product.5 9 Consequently,
54. Developments in the Law, supra note 47. at 653 (citing see, e.g., U1nited
States v. I 14 Dozen Packages of Mrs. Moffat's Shoo Fly Powders for
Drunkenness, 40 F. Supp. 208 (W.D.N.Y. 1941)) (stating on its label that an article
was "for drunkenness" was held tantamount to advertising it as a cure or treatment
for drunkenness).
55. United States v. Dotterweich, 320 U.S. 277 (1943).
56. Id. at 280.
57. Edward M. Basile & Melanie Gross, The First Amendment and Federal
Court Deference to the Food and Drug Administration: The Times They Are AChangin', 59 FOOD & DRUG L.J. 31, 34 (2004).

58. See, e.g , Interim Guidance on the Voluntary Labeling of AIilk, supra note 4,
at 6280.
59. See id. at 6280 (" However, even such a statement, which asserts that rbST
has not been used in the production of the subject milk, has the potential to be
misunderstood by consumers. Without proper context, such statements could be
misleading. Such unqualified statements may imply that milk from untreated cows
is safer or of higher quality than milk from treated cows. Such an implication
would be false and misleading."); See Guidance for Industry: Voluntary Labeling
Indicating Whether Foods Have or Have -Not Been Developed Using
http:x/www.fda.gov/
Guidance, FDA.gov,
Bioengineering; Draft
FoodC/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabel
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where the agency used to require manufacturers to disclose more, it
has moved away from this approach in many respects.60 Under the
guise of consumer confusion, the agency now attempts, through
voluntary guidance, to influence the actions of producers who
voluntarily disclose that they have not used certain processes or
additives that might be considered harnful. 6 1 This represents what
appears to be a significant departure from the agency's position in its
infancy.
Currently, the FDA maintains its authority under the FDCA is
limited to requiring the labeling of products that are misbranded
because of "false or misleading" 62 labeling. To determine whether a
product's labeling is false or misleading, the agency must consider
"the extent to which the labeling or advertising fails to reveal facts
material ... with respect to the consequences which may result from
the use of the article to which the labeling or advertising
relates ...under such conditions of use as are customary or usual."6 3
The FDA's interpretation of the FDCA authorizes them to require
mandatory labeling of foods that have the potential to be misbranded
only when the labeled feature involves facts material to possible
consequences of the use of the food product due to some material
chemical difference in what the food actually is versus what it
purports to be on the label. Unfortunately, the Act provides no
guidance as to what might be considered a "material fact" and this is
detennined by the agency on a case by case basis.
While the provisions of the current Act closely resemble the
language included in the 1906 Act, in practice, the FDA approaches
them very differently than it did in the early years of regulation.
Specifically, the agency appears to have adopted a position that tends
ingNutrition/ucm059098.htm, (last visited October 13, 2011) ("A statement that a
food was not bioengineered or does not contain bioengineered ingredients may be
misleading if it implies that the labeled food is superior to foods that are not so
labeled. FDA has concluded that the use or absence of use of bioengineering in the
production of a food or ingredient does not, in and of itself, mean that there is a
material difference in the food.").
60. See Interim Guidance on the Voluntary Labeling of Milk, supra note 4, at
6280. See also Guidancefor Industoy, supra note 58.
61. See Interim Guidance on the Voluntary Labeling of Milk, supra note 4, at
6280. See also Guidancefor Industoy, supra note 58.
62. 21 U.S.C. 343(a)(1).
63. Id. at § 321 (n).
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to favor industry rather than full disclosure aimed at consumer
protection and access to information. Despite mounting public
concern over genetically engineered food 65 and consumer requests
for the FDA to require more mandatory disclosure labeling,66 the
agency consistently states it lacks authority under the FDCA to
require specific labeling of food products based on consumer interest
alone. 67 Moreover, with regard to voluntary labeling, the agency's
guidance cautions producers and manufacturers to be careful in their
statements about the production of food, recommending that they
avoid misleading consumers into believing a product is superior to a
similar or identical product that has been processed differently. 8
These issues regarding both mandatory and voluntary food labeling
have been central to the debate over milk from cows treated with
rBST.
II. FDA's APPROVAL OF RBST AND RESULTING CHALLENGES

A. Introduction ofrBST to the Market
Marketed "as an important tool to help dairy producers improve
the efficiency of their operations and produce more milk more
sustainably" 69 and one that can "effectively reduce the environmental
impact of dairy operations,"7o rBST has been the subject of intense
scrutiny since Monsanto's application for FDA approval of the
supplement in 1987.n Posilac'C, or Monsanto's commercial version
of rBST is a genetically engineered "supplement of the naturally
64. See Basile & Gross, supra note 56, at 3 1.
65. See Id.
66. See Id.
67. Background Document: Public Hearing on the Labeling of Food Made
from the AquA dvantage Salmon Food and Drug Administration., FDA., 6 (Aug.
2010),
http://vww.fda.gov/downloads/Food/LabelingNutrition/
FoodLabelingGuidanceRegu latoryinformation/Topic-SpecificLabe linginformation/
UCM223913.pdf.
68. Id at 3.
69. Monsanto to Pursue Divestiture of POSILAC, MONSANTO (Aug. 6, 2008,
10:17AM), http://monsanto.mediaroom.com/index.php?s=43&item=626.
70. Id.
71. Margaret Sova McCabe, Got Controversy? Milk Does, 13 DRAKE J. AGRIC.
L. 475, 478 (2008) (citing Robert Collier, Regulation of rBST in the U.S., 3
AGBIOFORUM 156 (2000)).

2]MILKING IT

2011]

115

occurring cow hormone BST, that when administered to cows allows
them to produce more milk." 72 Its natural counterpart, bovine
somatotropin (BST), is produced in the pituitary glands of mature
cows to control their lactation cycles.73
In the 1930s, British scientists injected BST taken from deceased
cows into living ones and discovered that it had the potential to result
in increased milk production. 74 This process is largely inefficient on
a commercial scale due to the very small quantities that can
reasonably be extracted from each carcass. 5 However, the
introduction of recombinant DNA techniques in the 1980s allowed
for the development of rBST, which mimics BST and can be
produced inexpensively on a large scale.76
B.

Early Safety Concerns about the Use of rBST

Prior to its final approval for the use of rBST for animals, the FDA
approved the drug for "research purposes only"7 7 pending completion
of its full investigative process, but permitted milk and beef products
from cows treated with the hormone to be sold and consumed
pending approval.7 8 The General Accounting Office examined the
agency's investigational review of Monsanto's application, following
the preliminary approval, to determine whether the agency had

72. Milk Labeling - Is Monsanto Opposed to Truth in Labeling?, MONSANTO,
http://www.monsanto.com/newsviews/Pages/milk-labeling.aspx (last updated July
16, 2009).
73. Dan L. Burk, The Milk Free Zone: Federal and Local Interests in
Regulating Recombinant BST 22 COLUM. J. ENVTL. L. 227, 230 (1997) (citing

William H. Daughadav & David M. Barbano, Bovine Somatotropin
Supplementation ofDairy Cows: Is the Milk Safe?, 264 JAMA 1003 (1990)).
74. Emily Marden, Recombinant Growth Hormone in the Courts: In Search of
Justice, 46 DRAKE L. REV. 617. 621 (1998) (citing SHELDON KRIMSKY & ROGER P.
WRUBEL,

AGRICULTURAL

BIOTECHNOLOGY AND THE ENVIRONMENT:

SCIENCE,

POLICY AND SOCIAL ISSUES, 167-68 (1996)).

75. Id.; Burk, supra note 72, at 231.
76. Judith C. Juskevich & C. Greg Guyer., Bovine Growth Hormone: Human
FoodSafety Evaluation,249 SCI 875 (1990).
77. U.S. GENERAL ACCOUNTING OFFICE, B-248450, RECOMBINANT BOVINE
GROWTH HORMONE: FDA APPROVAL SHOULD BE WITHHELD UNTIL MASTITIS

ISSUE is RESOLVED 2 (1992).

78. Id.
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conducted a thorough investigation.79 As part of its review process,
the FDA required Monsanto to perform studies assessing whether
rBST was biologically absorbed into the body, and could have
required Monsanto to perform additional studies to deternine its
potential impact of bodily organs, in particular the liver.80 Monsanto
administered the hormone orally to rats over a 28- day period at 100
times the dose approved for administration to dairy cows.81 The study
found, and the FDA concurred, the rats did not demonstrate
absorption of biologically active rBST.82 The expert panel retained
for the preparation of the GAO Report later substantiated this finding
and determined that rBST was safe for use.8 3
The GAO's expert panel supported the FDA's findings in most
respects with one critical exception. The panel noted that while the
FDA's investigation largely considered the direct risks of rBST on
human health and food safety, the agency had failed to consider the
indirect human food safety risks that could result from negative
health impacts to animals injected with the drug.84 In reaching this
conclusion, the GAO focused on the increased risk of cattle treated
with rBST to develop mastitis, an infection of the udder, wvhich
producers often treat with antibiotics that can remain in milk in trace
amounts. The GAO expressed concern that antibiotic residue levels
in milk were already at unsafe levels due to the FDA's inadequate
survey system, which made the agency's failure to assess whether the
use of rBST would further increase the levels of antibiotics in milk
even more problematic. 86
79. Id.
80. Report on the Food and Drug Administration's Review of the Safety of
Recombinant
Bovine
Somatotropin,
FDA.GOV,
http://www.fda.gov/
AnimalVeterinary/SafetyHealth/ProductSafetyinformation/ucm 130321 .htm
(last
visited September 1., 2011) [hereinafter Report on the Food and Drug
Administration's Review] (the FDA updated this study in response to the report
issued by Health Canada, the Canadian counterpart to the FDA).
81. Id.
82. Id.
83. U.S. GENERAL ACCOUNTING OFFICE, supra note 76, at 6.
84. Id.
85. Id. at 9.
86. Id. (citing U.S. GENERAL ACCOUNTING OFFICE, GAO/RCED-91-26, FOOD
SAFETY AND QUALITY: FDA SURVEYS NOT ADEQUATE TO DEMONSTRATE SAFETY
OF MILK SUPPLY (1990) . The GAO panel's concerns with regard to the agency's

inadequate surveys were not unfounded. See Philip James Kijak, FDA Validates
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Interestingly, the GAO report also raised concerns about the
FDA's unwillingness to label food products derived from animals
treated with investigational drugs. 7 While the agency agreed in
principle that this was an issue that needed to be addressed in the
future, it felt this was the wrong situation to require such labeling, as
it had determined rBST presented no risk to human health.88 The
FDA largely agreed with the GAO report's findings, but on this point
the two diverged: as the GAO report stated, "we believe the public
should have the right to know which food products have been
produced from animals being tested with investigational drugs."89
C. FDA Approval ofrBST and the Resulting Challenges
Despite concerns over the safety of rBST for both animals and
humans, the FDA approved the use of the artificial hormone in 1993,
asserting it was "safe and effective for dairy cows, that milk from
rBST treated cows [was] safe for human consumption, and that
production and use of the product [did] not have a significant impact
on the enviromnent." 90 The agency determined "there was no
significant difference between milk from treated and untreated
cows."9I Consequently, the agency issued guidance to the industry
stating that because it did not find a compositional difference existed

Rapid Screening Tests for Antibiotics in Milk, FDA.GOV, http://www.fda.gov/
AnimalVeterinary/NewsEvents/FDAVeterinarianNewsletter/ucmO93 812.htm (last
updated Oct. 28, 2009) ("The screening tests are meant to be fast and accurate.
They are not meant to supply complete information about the potential of
antibiotics in milk. For instance, most kits will not test for all six beta-lactam drugs.
And, in most cases, the tests do not provide information on what drug caused the
positive result. Still, the screening tests fulfill their principal duty keeping the
milk supply in the United States safe-while not slowing down delivery of fresh
milk to consumers.").
87. U.S. GENERAL ACCOUNTING OFFICE, supra note 76, at 11.

88. Id.
89. Id.
90. Interim Guidance on the Voluntary Labeling of Milk supra note 4, at 6280;
see also Animal Drugs, Feeds, and Related Products; Sterile Sometribove Zinc
Suspension, 58 Fed. Reg. 59,946 (Nov. 12, 1993) (to be codified at 21 C.F.R pts.
510, 522) (approving the use of rBST).
91. Interim Guidance on the Voluntary Labeling of Milk, supra note 4, at 6280.
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in the two types of milk, it was unable to require mandatory labeling
of milk from cows treated with rBST . 2
The FDA went a step further and addressed what types of
statements would pass scrutiny under the FDCA for producers who
wished to include information about milk produced from cattle not
treated with the hormone. In its guidance, the agency advised
producers to tailor the statements on their labels to focus on process
rather than composition, and include an appropriate disclaimer noting
that the FDA found no significant difference between the two types
of milk.93 In other words, the FDA encouraged manufacturers and
producers who did not use rBST to ensure their statements did not
lead consumers to infer that their milk was of a superior quality. 94
The FDA's findings regarding the safety of rBST were later
challenged by two advocacy groups, the Vermont Public Interest
Research Group ("VPIRG") and Rural Vernont following the release
of a Canadian report prepared for Health Canada (the Canadian
counterpart to the FDA). This report, completed in 1999, noted a
number of potential risks to humans based on a ninety (90) day study
submitted by Monsanto for approval in the European Union ("EU"),
which was allegedly also submitted to the FDA during its approval
process. 95
The Canadian report made several findings that the GAO panel had
also addressed and that continue to fuel debate over the safety of
rBST. 96 Specifically, the Canadian panel found that Monsanto's 90day rat study demonstrated an antibody response to rBST, leaving

92. Id.
93. Id.
id,
95. Report on the Food and Drug Administration'sReview., supra note 79.
96. Report of the Royal College of Physicians and Surgeons of Canada- Expert
94. See

Panel on Human Safety of rBST, HEALTH CANADA, http://vww.hc-sc.gc.ca/dhp-

mps/vet/issues-enjeux/rbst-stbr/rep rcpsc-rapcrmcc final-a-eng.php#hebfp
(last
visited September 1, 2011) [hereinafter Royal College of Physicians and Surgeons
of Canada] ("bST does cause increased production of IGF-I and may, on the basis
of rat studies, cause an antibody response in some recipients of oral dosing. The
latter response warrants ftrther study in order to determine the likelihood of human
hypersensitivity reactions. The implications of human exposure to slightly
increased IGF-1 production (1% increment over normal exposure) would be
impossible to study in any animal or human model.").
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open the question of a hypersensitivity response in humans. 97
Additionally, as both the FDA and the GAO reports noted, milk from
rBST-treated cows contains an increased concentration of Insulinlike Growth Factor 1 ("IGF-1"). The complete effects of IGF-1 were
then unclear, 98 but in the panel's opinion, greater concentrations of
IGF-1 in humans could potentially result in an increased risk of
cancer for specific individuals. 99 The Canadian panel also expressed
concern over the increased possibility for cattle treated with rBST to
develop mastitis.100 The panel concluded that Health Canada had
enough information to make a decision about whether to approve the
use of rBST, however, it stated, "[t]he only definitive proof of
absolute safety of milk from rbST-treated cattle would be long tenn
follow up data in a population exposed to the resulting food
products."' 0 ' In response to these findings, Health Canada ultimately
chose not to approve Monsanto's application. 102
1. Stauber v. Shalala
The case the FDA relies upon to support its claims regarding its
inability to require mandatory labeling of milk products from cows
injected with rBST was filed in immediate response to the agency's
approval of the artificial growth hornone and provides the basis for
the agency's continued refusal to mandate labeling in this context. 0 3
97. Id
98. Id.
99. Id
100. Id; see also Evaluation and Use of Antimicrobial Drug Screening Tests,
U.S. Department of Health & Human Services, http://www.fda.gov/
Food/FoodSafety/Product-Specificinformation/MilkSafety/CodedMemoranda/
Memorandaoflnformuation/ucm082165.htm (last updated June 18, 2009) (Stating
that five of the eleven approved drugs to treat mastitis can cause hypersensitivity in
certain individuals and that there is no ideal test, as it cannot identify the specific
drug residue nor its concentration.) (stating that five of the eleven approved drugs
to treat mastitis can cause hypersensitivity in certain individuals and that there is no
ideal test, as it cannot identify the specific drug residue nor its concentration.).
101. Royal College of Physicians and Surgeons of Canada, supra note 95.
102. Drugs and Health Products, HEALTH CANADA, http://www.hc-sc.gc.ca/dhpmps/vet/issues-enjeux/rbst-stbr/index-eng.php (last modified Oct. 1, 2004).
103. See Background Document, supra note 66 (citing 72 Fed. Reg. 16291,
16294 (Apr. 4, 2007); 59 Fed. Reg. 6279 (Feb. 10, 1994); Stauber v. Shalala, 895
F. Supp. 1178, 1193 (W.D. Wis. 1995)) ("Fifth, FDA cannot require additional
labeling about production methods unless it is necessary to ensure that the labeling
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In Stauber v. Sha/ala. 104 the United States District Court of
Wisconsin considered the issues on the parties' cross motions for
surmnary judgment, finding in favor of the defendants, Donna
Shalala, then Secretary of Health and Human Services, and David
Kessler, then Commissioner of the FDA. 05 In addition to arguing
that the FDA's decision to approve the drug was arbitrary and
capricious because of the agency's failure to consider the health and
safety effects of rBST, the plaintiffs, consumers of commercial dairy
products, argued that the FDCA required the agency to mandate
labeling of any products derived from cows treated with rBST due to
"material facts"' 0 6 about the differences in the milk.107
The plaintiffs advanced two theories to support their argument
regarding labeling. First, milk from rBST-treated cows
is
0
organoleptically' o different from milk from untreated rBST cows.' 09
Second, the "widespread consumer desire for mandatory labeling of
rBST-derived milk"' 10 evidenced a degree of demand which, in turn,
amounted to a material fact triggering the labeling requirements
under the FDCA. 11 '
Under section 201(n) of the FDCA,
"[i]nformation disclosing differences in performance characteristics
(e.g., physical properties, flavor characteristics, functional properties
is not false or misleading. Another way of stating this point is that FDA cannot
require labeling based solely on differences in the production process if the
resulting products are not materially different due solely to the production process.
For example, recombinant Bovine Somatotropin ("rBST") is a synthetic growth
hormone that increases milk production in dairy cows. Because FDA found that
there was no material difference between milk from rBST-treated cows and milk
from non-rBST-treated cows, FDA did not have the authority to require additional
labeling of milk from rBST-treated cows.").
104. Stauber v. Shalala, 895 F. Supp. 1178 (W.D. Wis. 1995) (Stauber was
originally commenced with forty-one (41) plaintiffs as Barnes v. Shalala, 865 F.
Supp. 550 (W.D. Wis. 1994). The court in Barnes granted the defendant's motion
to dismiss based on a lack of standing for all those plaintiffs that were not
consumers. The remaining five (5) consumers were the plaintiffs in Stauber.).
105. Stauber, 895 F. Supp. at 1183.
106. Id at 1182.
107. Id
108. The FDA defines organoleptic properties as "those that stimulate the
sensory organs., such as texture or aroma." BackgroundDocument, supra note 66.
109. Stauber, 895 F. Supp. at 1193.
110. Id
111. Id
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and shelf life) is a material fact under section 201(n) of the act
because it bears on the consequence of the use of the article."" 2
Consequently, any failure to disclose this information to the
consumer on the label was misleading, causing the product to be
misbranded under section 403(a)."'
The plaintiffs submitted evidence to substantiate their claims that
rBST has a negative impact on human health largely in the form of
affidavits, which the court noted were not given to the FDA during
the approval process, and therefore, could not be considered.114 The
court found that the plaintiffs also relied on an affidavit from Dr.
Richard Burroughs,' 5 a veterinary medical officer for the FDA who
had participated in the Posilac'c review process.1 16 Because the
plaintiffs presented this affidavit to support the proposition that rBST
can have serious negative health consequences for cows, the court
considered it solely in that regard, and accepted the facts regarding
negative health consequences to cattle as undisputed." 7
Dr.
Burroughs' affidavit also cited several critical flawvs in the agency's
review of the drug, as well as concerns about Monsanto's testing
112. Id.
113. Id. 21 U.S.C. § 403(a) (current version at 21 U.S.C. § 343(a)(1) (2010)) ("A
food shall be deemed to be misbranded-(a) If (1) its labeling is false or misleading
in any particular, or (2) in the case of a food to which section 411 applies, its
advertising is false or misleading in a material respect or its labeling is in violation
of sec. 411(b)(2).").
114. Stauber, 895 F. Supp at 1190 ("Plaintiffs cannot ask this court to rely on
opinions within the medical community regarding health risks posed by rbST
without first establishing that those opinions were presented to the FDA before it
granted approval of Posilac."); see Marden, supra note 40, at 634 (suggesting that
the court unnecessarily expanded the scope of the rule barring judicial review of an
agency's findings to prohibit review of "nonagency" data outside the record).
115. Burroughs was terminated from the FDA in 1988, allegedly for
incompetence. Upon his firing, Burroughs made public statements about the
FDA's review of rBGH alleging that the agency was ignoring problems with the
drug while Monsanto was manipulating the data. Burroughs was reinstated after it
was determined he was improperly fired. However, his allegations were taken
seriously enough that the GAO was asked to investigate the issue leading to the
report mentioned above. FOOD AND WATER WATCH, RBGH: How ARTIFICIAL
HORMONES DAMAGE THE DAIRY INDUSTRY AND ENDANGER HUMAN

(June 2009).
116. Stauber, 895 F. Supp. at 1190.
117. Id.

HEALTH, 2
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processes.118 While this information could have been useful to
clarify the record before the agency or to illuminate the alleged
capriciousness of the agency's decision-making process, the court
would not consider the affidavit in that light, as it was not proffered
for that purpose.119
The Stauber court was sympathetic to the issues raised by the
plaintiffs, but ultimately deferred to the findings of the agency
regarding the safety of rBST, holding that the decision to approve the
hormone was not arbitrary and capricious.120 The court then
analyzed the issue of mandatory labeling under the FDCA. With
regard to this issue, the court found that plaintiffs failed to point to
evidence in the record proving that milk from rBST-treated and
untreated rBST cows differ in terms of performance characteristics or
organoleptic properties. 12 1 Specifically, the plaintiffs failed to
demonstrate that the administration of rBST has an impact on the
composition of milk. 122
The plaintiffs also argued that widespread consumer demand for
labeling information about milk from cows treated with rBST
necessitated mandatory labeling under the FDCA.123 However, when
deciding which facts to require on labels, the FDA may only consider
consumer demand when it has first determined that the product is
different than what it claims to be, and that then determined that the
difference is one about which consumers would want to know.124 In
other words, even if consumers viewed the product as different, the
FDA could not require labeling unless a material difference exists
between the two products.1 25 The Stauber court held that the
"plaintiffs [did] not present[] any evidence demonstrating
organoleptic differences between regular and rbST-derived milk or of
any harmful effects of rbST on consumers,"1 26 therefore, a label

118. Id
119. Id (citing Citizens to Preserve Overton Park v. Volpe., 401 U.S. 402, 420-21
(1971)).
120. Stauber, 895 F. Supp. at 1192.
121. Id at 1193.
122. Id
123. Id
124. Id
125. Id
126. Id
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stating the milk was derived from cows treated with rBST would
constitute misbranding under the Act.127
In some respects, the Stauber decision does not seem to reflect a
departure from the original cases interpreting the FCDA's
misbranding provisions. The court deferred to the agency's decision
not to require labeling based on its finding that no material difference
existed between milk from cows treated with rBST and those that
were not. This holding has been upheld in cases following the
Stauber decision.128 However, what is striking about the Stauber case
is the agency's departure from its previous role of preventing
consumer fraud by erring on the side of caution and giving
consumers more, rather than less, information about the products
they are purchasing.
III. STATE LEGISLATIVE RESPONSE AND FIRST AMENDMENT
CHALLENGES

A. InternationalFoods v. Amestoy
In response to the FDA's unwillingness to require labeling of
products from cattle treated with rBST, the Vermont legislature
enacted a statute mandating the labeling of milk and milk products

127. Id.
128. This holding has been upheld in cases following the Stauber decision.
Specifically, in Alliance for Bio-Integrity v. Shalala, the plaintiffs challenged the
FDA's decision to recognize foods altered through recombinant DNA technology
as safe and not require mandatory labeling. The court in Alliance for Bio-Integrity
cited Stauber finding "Plaintiffs fail to understand the limitation on the FDA's
power to consider consumer demand when making labeling decisions because they
fail to recognize that the determination that a product differs materially from the
type of product it purports to be is a factual predicate to the requirement of
labeling. Only once materiality has been established may the FDA consider
consumer opinion to determine whether a label is required to disclose a material
fact. Thus, 'if there is a [material] difference, and consumers would likely want to
know about the difference, then labeling is appropriate. If, however, the product
does not differ in any significant way from what it purports to be, then it would be
misbranding to label the product as different, even if consumers misperceived the
product as different.'" Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166,
179 (D.D.C. 2000) (citing Stauber, 895 F. Supp. at 1193).
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sold within the State that were derived from rBST-treated cows. 129
The legislature cited "strong consumer interest" and the "public's
'right to know'" as the bases for the law.1 30 In response, a group of
dairy manufacturers challenged the constitutionality of the law under
the First Amendment and the Commerce Clause, and requested
injunctive relief to prevent its enforcement.13 1 The Second Circuit
Court of Appeals ultimately decided the case on First Amendment
grounds and did not reach the Commerce Clause issues. 2With
regard to a showing of irreparable harm, the court reversed the lower
court's decision, holding that because the statute required the dairy
manufacturers to speak when they desired to remain silent, it
"'contravene[d] core First Amendment values,'" which resulted in
irreparable harm to the plaintiffs.1 33
The court also determined that the plaintiffs successfully
demonstrated they would likely be successful on the merits. 13 Using
the four part test articulated in Central Hudson,1s which pertains to
commercial speech, the court considered: "(1) whether the expression
concerns lawful activity and is not misleading; (2) whether the
governments interest is substantial; (3) whether the labeling law
directly serves the asserted interest; and (4) whether the labeling law
is no more extensive than necessary."1 36 Regarding the second
prong, the court found that the State failed to demonstrate it had a
substantial interest in requiring labeling of milk products from cattle
treated with rBST because it did not ""claim that health or safety
concerns prompted the passage of the Vermont Labeling Law,'""37
129. Int'l Dairy Foods Assn. v. Amestov, 92 F.3d 67, 69 (2d Cir. 1996) (citing 6
V.S.A. § 6754 (1995)) ("If rBST [a recombinant bovine growth hormone] has been
used in the production of milk or a milk product for retail sale in this state, the
retail milk or milk product shall be labeled as such.").
130. Int'l Dairy Foods Assn. v. Amestoy, 898 F. Supp 246, 249 (D. Vt. 1995)
(rev'd92 F.3d 67 (2d Cir. 1996).
13 1. Int'l Dairy Foods.,92 F. 3d at 70.
132. Id.

133. Id. at 72 (citing Int'l Dairy Foods, 898 F. Supp. at 251-52; Paulsen v.
County of Nassau, 925 F.2d 65, 68 (2d Cir. 1991)).
134. Id.
135. Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n, 447 U.S. 557, 566
(1980).
136. Int'1 Dairy Foods., 92 F.3d at 72 (citing Central Hudson, 447 U.S. at 566).
137. Idat 73.
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rather, it cited consumer interest and the public right to know.1 38 In
the court's opinion, these interests were not sufficient to deprive the
plaintiffs of their First Amendment rights.1 9
Following the same reasoning as Stauber,14 0 the court noted it was
not aware of any cases justifying a requirement that manufacturers
disclose warning information about production methods on the basis
of consumer interest alone, when the methods have no discernable
impact on the final product.141 Specifically, because the FDA
determined rBST has no "appreciable effect on the composition of
milk produced by treated cows,"1 42 the requirement that
manufacturers disclose Whether their cattle have been treated with the
drug has no discernable connection to public health, safety, or
welfare.143 Under this holding, even Where a statement on a label is
factually accurate and truthful, unless the State can demonstrate the
warning is necessary to prevent hann, deception, or confusion, the
language on the label cannot be sustained under the First
Amendment. 4 4
HWhile the State of Vennont attempted to provide more information
to consumers by mandating labeling in response to the agency's
failure to do so, other states approached the issue differently and
enacted restrictive labeling laws to comply with the voluntary

138. Id
139. Id
140. Stauberv. Shalala, 895 F. Supp. 1178, 1193 (W.D. Wis. 1995).
141. Int'1DairyFoods, 92 F. 3d at 73. (2d Cir. 1996).'
142. Id (citing Int'l Dairy Foods Assn. v. Amestoy, 898 F. Supp. 246, 248
(D.Vt. 1995)).
143. Id
144. See id. at 74 (citing United States v. Sullivan, 332 U.S. 689, 693 (1948)
(upholding federal law requiring warning labels on "harmful foods, drugs and
cosmetics") (emphasis added); see also Zauderer v. Office of Disciplinary Counsel,
471 U.S. 626, 651 (1985) (disclosure requirements are permissible "as long as
[they] are reasonably related to the State's interest in preventing deception of
consumers."); In re R.M.J., 455 U.S. 191, 201 (1982) ("warning[s] or disclaimer[s]
might be appropriately required ... in order to dissipate the possibility of consumer
confusion or deception."); Bates v. State Bar of Arizona, 433 U.S. 350, 384 (1977)
(state bar association could not ban advertising that was neither misleading nor
deceptive); Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council,
Inc., 425 U.S. 748, 771-72 (1975) (regulation aimed at preventing deceptive or
misleading commercial speech would be permissible)).

126

FORDHAM ENVIRONMIENTAL LAW REVIEW

[VOL. 23.1

labeling standards set forth by the agency's guidance. 145 The State of
Ohio went so far as to prohibit any labeling including terms such as
"rBST free," or "rBGH-free," due to the potential for confusion
among consumers, which led to the most recent legal challenge
regarding milk labeling.146
IV. INTERNATIONAL DAIRY ASSOCIATION V. BOGGS AND MOVING
FORWARD

A.

The Boggs Decision - Acknowledging a Compositional
Difference

To address consumer demand for dairy products from cattle not
treated with rBST, dairy processors in Ohio began including
information on their labels stating that they did not use rBST in the
production process.147
Governor Ted Strickland responded by
issuing an executive order directing the Ohio Department of
Agriculture ("ODA") to "define what constitutes false and
misleading labels on milk and milk products."1 48 The ODA proposed
a rule that aimed to restrict the types of comments dairy processors
could include on their products. 149 For example, any compositional
claims stating "No Hormones", "Honnone Free", "rBST free", rGBH
free", "No Artificial Honnones", or "bST Free" were deemed "false
and misleading" under the rule regardless of the inclusion of any
disclaimers about the FDA's findings.1 0 The results of two public
hearings and many public comnents on the proposed rule suggested
that, by and large, Ohioans disfavored the suggested labeling
restrictions. 151 Specifically, "[1]ess than 70 of the 2,700 emails and
letters sent to the ODA during this time period were in favor of the

145. E.g., Pa. Dep't. of Agric.: Milk Labeling Standards 2.0.1.17.08 (Jan. 17,
2008), S.B. 595, 2008 Sess. (Kan. 2008); H.B. 1300 115th Gen. Assemb., 2d Reg.
Sess. (Ind. 2008).
146. Ohio Emergency Rule, Dairy Labeling, 901:11-8-01 (May 22, 2008).
147. Int'l Dairy Foods Ass'n. v. Boggs, 2009 WL 937045, 5 (S.D. Ohio).
148. Int'l Dairy Foods Ass'n v. Boggs, 622 F.3d 628, 634 (6th Cir. 2010) (citing
Ohio Governor Executive Order 2008-03S (Feb. 7, 2008)).
149. Id.
150. Id.
151. Id.
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proposed rule."1 52
Despite the tremendously negative public
response, ODA Director, Robert Boggs, adopted the rule, as
originally proposed, in May 2008.153
Both the International Dairy Foods Association ("IDFA") and the
Organic Trade Association ("OTA") filed lawsuits, which were
ultimately consolidated, challenging the constitutionality of the
rule. 54 The plaintiffs moved for a preliminary injunction; thereafter,
both parties sought summary judgment on all issues with the
exception of an equal protection claim. The district court granted
152. Id.
153. Id. In pertinent part., the rule provides:
A) Pursuant to sections 917.05 and 3715.60 of the Revised Code,
dairy products will be deemed to be misbranded if they contain a
statement which is false or misleading.
(B) A dairy label which contains a production claim that "this milk is
from cows not supplemented with rbST" (or a substantially
equivalent claim) may be considered misleading on the basis of such
language, unless:
(1) The labeling entity has verified that the claim is accurate, and
proper documents, including, but not limited to, producer signed
affidavits, farm weight tickets and plant audit trails, to support the
claim, are made readily available to ODA for inspection; and
(2) The label contains, in the same label panel, in exactly the same
font, style, case, and color and at least half the size (but no smaller
than seven point font) as the foregoing representation, the following
contiguous additional statement (or a substantially equivalent
statement): "The FDA has determined that no significant difference
has been shown between milk derived from rbST-supplemented and
non-rbST-supplemented cows."
(C) Making claims regarding the composition of milk with respect to
hormones, such as "No Hormones", "Hormone Free", "rbST Free",
"rbGH Free", "No Artificial Hormones" and "bST Free", is false and
misleading. ODA will not permit such statements on any dairy
product labels.
(D) Statements may be considered to be false or misleading if they
indicate the absence of a compound not permitted by the United
States [Flood and [D]rug [A]dministration to be present in any dairy
product, including, but not limited to antibiotics or pesticides. Except
as otherwise provided in this rule, accurate production claims will
not be deemed false or misleading.
Ohio Admin. Code §901:11-8-01 (2008).
154. Boggs, 622 F.3d at 634.
155. Id.
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surnary judgment in favor of the State on virtually every claim
except the one pertaining to the rule's restrictions on production
claims, on which it granted partial summary judgment.15 6 Because of
the rulings on summary judgment, the court found the plaintiffs could
not demonstrate that they were likely to prevail on the merits, and
denied the request for a preliminary injunction. 1 The plaintiffs then
filed an interlocutory appeal of only the First Amendment and
Commerce Clause claims.' 58
1. First Amendment Challenge to Restriction on Composition
Claims
The plaintiffs first argued that the rule's prophylactic ban on any
composition claims such as "rBST- free," antibiotic-free," or
"pesticide-free" violated the First Amendment.159 Using the same
four part test from Central Hudson applied by the Amestoy court to
consider whether the speech, characterized as commercial, was
entitled to First Amendment protection,' 60 the court agreed with the
plaintiffs, holding the rule was more extensive than necessary to meet
the State's interest in preventing consumer confusion or deception. 16 1
a. Inherently Misleading
The court adopted the plaintiffs reasoning, holding that "wvhere
speech is only potentially misleading... .'the preferred remedy is
more disclosure rather than less."' 1 62 Whereas the district court held
the composition claims were inherently misleading because they
implied a compositional difference between the two milks,
contradicting the FDA's findings relative to that issue, the court of
156. Id
157. Id at 635.
158. Id
159. Id.; Ohio Admin. Code §901:11-8-01(C)(2008).
160. See Int'l Dairy Foods Ass'n. v. Amestoy, 92 F. 3d 67, 72 (2d Cir. 1996).'
161. Boggs, 622 F.3d at 639 (citing Central Hudson Gas & Elec. Corp. v. Public
Serv. Comm'n, 447 U.S. 557 (1980)).
162. Id at 636 (citing In re R.MIJ, 455 U.S. 191, 203 (1982); Bates v. State Bar
of Arizona, 433 U.S. 350. 374-75 (1977) ("striking down a ban on advertising for
routine' legal services in part because 'it seems peculiar to deny the consumer, on
the ground that the information is incomplete, at least some of the relevant
information needed to reach an informed decision"')).
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appeals found the record told a different story. 163 Specifically,
"contrary to the district court's assertion, a compositional difference
does exist between milk from untreated cows and conventional milk
('conventional milk,' as used throughout this opinion, refers to milk

from cows treated with rBST.)"16 4
The appellate court considered additional scientific information
outside the scope of the FDA's record to reach this finding, which
signifies a different approach than that of the district court."' In the
case below, the district court held a conference on the preliminary
injunction request at the start of the case 66 and asked the parties what
evidence they intended to present.167 According to the district court,
the Director of ODA suggested the defendants might need an expert
witness to testify about the science behind rBST, and the plaintiffs
disagreed, claiming the issues were "largely legal,"1 68 which led the
court to conclude that the parties did not dispute the FDA's scientific
findings regarding rBST.169 On appeal, the court chose not to strictly
rely on the FDA's findings regarding the science of rBST, and also
reviewed amici curiae evidence to make several findings relevant to
the First Amendment challenge.' 70
First, the appellate court determined that the use of rBST has been
shown to increase IGF-1 levels, which has been linked to certain
types of cancers.' 7' Second, rBST induces cattle to produce milk
during their "'negative energy phase"' 1 72 when they would not
normally produce milk, which causes that milk to be of lower quality
due to "increased fat content" and "decreased levels of proteins."
Milk from cattle treated with rBST also has a higher somatic cell
count, which can cause the milk to turn sour more quickly than milk
163. Id
164. Id
165. Id
166. Int'l Dairy Foods Ass'n v. Boggs, 2009 WL 937045, 5 (S.D. Ohio).
167. Id
168. Id
169. Id (citing Case no. 2:08-cv-628, Doc. 19, p.32).
170. Int'l Dairy Foods Ass'n v. Boggs, 622 F.3d 628, 636 (6th Cir. 2010).
171. Id
172. Id. (citing Brief for Center for Food Safety, et al. as Amici Curiae
Supporting Appellants., Int'l Dairy Foods Ass'n v. Boggs., 622 F.3d 628 (6th Cir.
2010) (No. 09-3515).
173. Id at 636-37.
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from untreated cows.174 Additionally, "and more salient to the
regulation of composition claims like 'rBST-free,"' 7 5 the inability to
detennine whether rBST is present in milk from cows treated with
the hormone is not because the drug is not present in the milk, but
because scientists have not yet developed a test to accurately detect
its presence.176 The court found the FDA's statement that it detected
"no significant difference"177 compelling, as it suggested the agency
left room for the finding that "some compositional difference
between the two types of milk may exist...."
Considering the evidence collectively, the appellate court held that
there were, in fact, "two distinct types of milk." 7 9 The first type of
milk comes from cattle not treated with rBST, meaning the milk can
never contain the hormone.8o The second type of milk comes from
cattle treated with rBST and may or may not contain rBST - but there
currently exists no test to determine whether it does.1
Because a
compositional difference exists between these two types of milk, and
it is impossible to determine whether conventional milk does, in fact,
contain rBST, a composition claim on a label for milk from untreated
cows stating the milk is "rBST free" is not inherently misleading.' 82
Such a label informs consumers "of a meaningful distinction" and.
"at worst potentially misleads them into believing that a
compositionally distinct milk adversely affects their health."' 8 3
b. SubstantialState Interest Directly Related to the Regulation.
Which is Not MWore Extensive Than Necessary
After making the determination that the composition claim "rBSTfree" was not inherently misleading, the court went on to consider the
remaining three factors under Central Hudson. First, the court
considered whether the State's interest in creating the rule was
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.

Id at 637.
Id
Id
Id
Id
Id
Id
Id

Id
Id
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substantial.1 84 The State's asserted interest in drafting the rule was
"to prevent the use of 'false or misleading' labeling."'"' While the
plaintiffs agreed this was a substantial interest because the rule was
targeted at consumer deception, the State was required to show that
"'the harms it recite[d] [were] real and its restriction [would] in fact
alleviate them to a material degree."' 1 86 Here, the State cited only the
FDA Guidance and the public comments to the draft proposed rule it
received from consumers to demonstrate the targeted deception. 87
The FDA Guidance did not provide any supporting evidence to prove
a real harm of consumer deception.
Additionally, the public
comments from consumers in response to the proposed rule
evidenced some consumer confusion regarding the presence of rBST
in conventional milk, but the confusion was not the result of product
labels, and, rather, appeared to originate from outside sources.' 89
Consequently, the court determined that the evidence simply did not
prove that consumers in Ohio have been misled by the labeling on
their milk and milk products, leading it to conclude that the rule did
not directly advance the State's asserted interest in preventing false
or misleading labeling and was "more extensive than necessary to
serve that interest."' 90
2.

First Amendment Challenge to Disclosures for Production
Claims

The court next addressed the production claims, stating, for
example, "this milk is from cows not supplemented with rBST."l91
184. Id. at 638.
185. Id (citing Ohio Admin. Code, 901:11-9-01(A) (2008).
186. Id (citing lbanez v. Fla. Dep't of Bus. and Prof I Regulation, Bd. Of
Accountancy., 512 U.S. 136, 146 (1994) (citation omitted)).
187. Id
188. Id ("The FDA suggests in the Guidance that the claim 'rbST free' 'may
imply a compositional difference' between the two types of milk, 59 Fed.Reg.
6279, 6280 (emphasis added), but this statement does not establish that such a
claim is necessarily misleading in every context. Furthermore, the FDA cited no
evidence or studies in the Guidance to support its concerns regarding consumer
confusion. The Guidance therefore does not constitute 'evidence of deception' as
required under Ibanez.").
189. Id at 639.
190. Id
191. Id. at 640.
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The Ohio rule required that these claims had to be accompanied by a
disclosure statement to inform the consumer that the FDA had not
found any significant difference between the two types of milk.192
Moreover, the Ohio rule required that the disclosure be included on
the same panel, "'in exactly the same font, style, case, and color and
at least half the size (but no smaller than seven point font)'" as the
claim addressing production.193
The plaintiffs argued the district court applied the wrong standard
of review by focusing on Zauderer v. Office of Disciplinary Counsel
of the Supreme Court of Ohio,' 94 which considered disclosure
requirements and did not apply the same strict standard as Central
Hudson.195 The court was unconvinced by this argument, holding
that Zauderer provided the appropriate standard, as it applied to
speech that was inherently misleading.196 This standard also
controlled speech that was only potentially misleading. 197
Under the Zauderer analysis, requirements pertaining to
disclosures must be "'reasonably related to the State's interest in
preventing deception of consumers' and cannot be 'unjustified or
unduly burdensome."' 98 The plaintiffs argued that the State failed to
demonstrate the production claims were deceptive or confusing to
consumers.199 The court rejected this argument despite the fact that
the FDA's guidance and the public comments submitted in response
to the draft rule provided only minimal evidence of deception or
confusion.200
This evidence, weak as it was, provided some
indication that claims about production can be confusing to
consumers in Ohio, who seemed unsure about the presence of rBST
in the milk they purchased. 20 1 Despite finding that the disclosure
requirement is reasonably related to the State's asserted interest in
preventing deception, the court found the requirement that such
disclosure be contiguous to the production statement was not
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.

Id (citing Ohio Admin. Code 901:11-8-01(B)(2)).
Id
Zauderer v. Office of Disciplinary Counsel., 471 U.S. 626, 638 (1985).
Int'l Dairy Foods Ass'n v. Boggs, 622 F.3d 628, 640 ( 6 ' Cir. 2010).
Id at 641.
Id
Id (citing Zauderer,471 U.S. at 651).
Id at 642.
Id
Id
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rationally related to the State's interest.202 The State was particularly
concerned over the use of asterisks next to the disclosure statements,
as it asserted (without supporting evidence) that asterisks have raised
issues in the past.20
The plaintiffs also argued that the Ohio rule was unduly
burdensome because it was significantly different from the rules in
other states, which would require manufacturers and processors to
make Ohio-specific labels.2 04 However, in the absence of the
restrictions on composition claims and asterisks, the Ohio rule
closely resembles the labeling regulations in other states. 205
B.

Conclusion

The end result of the decision in Boggs is the creation of a state
regulation in Ohio to address milk labeling that is not significantly
different from regulations in other states. However, this reading fails
to consider how the Boggs decision represents a dramatic departure
from prior cases addressing milk labeling. While the previous cases
deferred to the findings of the agency, reiterating its conclusion that
there is "no significant difference between milk from treated and
untreated cows,"207 the Boggs court considered new scientific
evidence that was outside the agency's record when it initially
approved the drug. 208 Moreover, the court relied in part on this
evidence to make the determination that a compositional difference
exists between milk from treated and untreated cows.209 Beyond the
fact that no court has looked outside the agency's record or made a
determination that a compositional difference between the two types
of milk exists, what is most compelling about the court's decision is

202.

Id at 643.

203. Id
204. Id

205. See, e.g., Wis. Admin. Code., ATCP § 83.02 (2004); Alaska Stat. §
17.20.013 (2011); Minn. Stat. § 32.75 (2004); New Jersey Dep't of Agric.' and
Dep't of Health and Senior Service's Joint Guideline for "NON-rBST" Claims
(2007); Title 61., Legislative Rule, West Virginia Dep't of Agric, Series 4D,
"Labeling of Dairy Products for rBST or rBGHI" (1995).
207. Guidancefor Industry, supra note 58.
208. Boggs, 622 F.3d at 636-37.
209. Id
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its reliance on the agency's language regarding its own findings. 210
The agency's findings state there is not a significant difference
between the two types of milk. 21 1 The slightly ambiguous nature of
this statement led the court to posit that the agency's language does
not preclude the possibility that a difference in the two types of milk
may, in fact, exist.212 The court followed this line of reasoning to
suggest that because the agency currently does not have a test to
determine whether milk from rBST-treated cows may contain the
hormone in trace amounts, the possibility that the milk might contain
hormones is too significant to be ignored. 213 Taking this particular
finding a step further and applying it to the language of the statute
itself, advocates may have a good argument to compel the FDA to
mandate labeling of milk from cows treated with rBST.
Commentators suggest that the age of deference to the FDA is
coming to an end, as the federal courts are more willing to strike
down agency decisions that ban or restrict commercial speech.2 14
Arguably, the Boggs decision provides another significant example
of a federal court's unwillingness to simply accept the agency's
determinations about the effects of a particular drug it approved
almost a decade prior. The court's findings regarding the effects of
rBST on human and animal health, as well as milk quality, reflect
what could be viewed as a distrust of the agency's own limited
findings signaled by its willingness to depart from the traditional
deference accorded to agency findings. Despite numerous requests in
the form of lawsuits and petitions to the agency to revisit its
conclusions about the safety of rBST, the agency has remained
steadfast in its approach and continues to maintain the drug is safe for
both animals and humans, as evidenced by the agency's continued
approval for use in dairy cattle. On February 15, 2007, a group of
210. See id at 637.
211. Id
212. Id
213. Id
214. See Basile & Gross, supra note 56, at 43 (analyzing the decision in
Thompson v. Whitaker, 248 F. Supp. 2d 1 (D.D.C. 2002) where the "the court went
beyond its typical judicial practice and conducted its own analysis of the scientific
data, ultimately substituting its interpretation of the data for the agency's. The
Whitaker court's approach not only stretched the limits under Chevron, and
arguably a departed from legal precedent., but its decision also has the potential to
undermine FDA's credibility in future decisions.").
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individuals filed the most recent petition, and requested the Secretary
of the FDA to "immediately suspend approval" of the drug based on
"imminent hazard" due to the scientific evidence showing increased
risks of cancer for individuals consuming treated milk. 217 According
to Samuel S. Epstein, one of the authors of the petition, the FDA did
not even acknowledge their filing.218 The petitioners resubmitted
their request for suspension of approval of the drug on January 12,
2010, and the Commissioner dismissed it on procedural grounds. 2 19
While advocates seeking labeling of milk from rBST-treated cows
have been unsuccessful to date, the Boggs decision at least affirms
producers' rights to claim that their untreated milk is "rBST-free,"
allowing consumers access to this desired information. However, in
many states, milk producers do not include this statement on their
labels for fear of legal challenges, or simply because the particular
state's requirements are too onerous.220 One suggestion is to ban the
drug altogether. However, the above example demonstrates that this
222
may not currently be the most viable choice. Another suggestion
includes encouraging the agency to allow statements such as "rBSTfree" without also requiring the disclosures about the FDA's
findings.2 2 3
A more ambitious solution would be to compel the agency to
mandate labeling of milk from cows treated with rBST. Given the
uncertainty for producers and manufacturers in the absence of
uniform regulation addressing the issue, mandatory labeling could be
less controversial than regulators fear. Contrary to its claims that it
cannot require labeling based on consumer interest alone, the agency
217. Citizen Petition from Samuel S. Epstein, et al. to Mike Leavitt, Secretary of
Health and Human Services
(February
15, 2007), available at
http://www.preventcancer.com/publications/pdf/FINAL PET withsig mayl77.pdf
(last visited September 1., 2011) (seeking the withdrawal of the new animal drug
application approval for Posilac - Recombinant Bovine Growth Hormone).
218. Samuel S. Epstein, The Dangers of Genetically Engineered AIilk, HUFFPOST
(July 30., 2010, 8:00 AM), http://vww.huffingtonpost.com/samuel-s-epstein/thedangers-of-geneticall b 633955.html.
219. Id.

220. See e.g.. West Virginia Dep't of Agric.. supra note 204 (West Virginia's
requirement that any claims regarding the absence of rBST have to be verified
through documentation and herd tracking.).
222. See Epstein.,supra note 214, at 495.
223. McCabe, supra note 70, at 495.
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currently requires food that has been irradiated to be labeled as
such.2 24 While individuals have questioned the safety of ionizing
radiation due to the chemical changes that can result from the
process, the agency has determined the process is safe and helps to
extend the shelf life of certain foods, while killing certain
infestations. 225
The agency notes that "like other forms of
processing, irradiation can affect the characteristics of food." 226
Therefore, "[c]onsumer choice mandates that irradiated food be
adequately labeled and under the general labeling requirements, it is
necessary that the food processor inform the consumer that food has
been irradiated.", 227 Interestingly, the agency requires labeling in this
instance despite the fact that it has deemed the process to be safe, and
possesses information to suggest that consumers have a negative
view of foods that have been irradiated due to their lack of
infonnation about the safety of the process.228
The decision in Boggs, coupled with the agency's willingness to
require labeling disclosing a process that can have a chemical impact
on food, suggests the issue of mandatory milk labeling may again be
ripe for review. The Boggs decision provides a framework by which
advocates can petition the agency to stop milking their justification
for failing to institute rulemaking, and demand the agency develop
rules to mandate the labeling of milk from cows treated with rBST,
based on the proven compositional difference between the two types
of milk. Such a label could state, "this milk comes from cows that
have been treated with rBST." As a practical matter, requiring this
label might not have an ill effect on the sale of conventional milk, as
consumers who have no preference will likely make their purchase
decision based on other factors. 229 The Boggs decision provides
support for this proposed label, as do as the agency's requirements
for labeling of irradiated foods.
224. Kim M. Morehouse & Vanee Komolprasert, Irradiation of Food and
Packaging,
FDA.GoV,
http://www.fda.gov/Food/FoodingredientsPackaging/
IrradiatedFoodPackaging/ucm081050.htm (last update May 4, 2009).

225. Id.

226. Id.
227. Id.
228. Id.
229. Donna M. Byrne, Cloned Mieat, Voluntary Food Labeling, and Organic
Oreos, 8 PIERCE L. REV. 31, 63 (2009).
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If such an effort is unsuccessful, advocates can take some solace in
the fact that, in the realm of milk and milk products, the market has
already begun to respond even where the law has failed. Consumers
have expressed a clear preference for products from cows that have
not been treated with rBST, and suppliers are listening. For example,
Wal-Mart recently issued a press release stating that the Great Value
milk offered in its stores comes from cows that have not been treated
with rBST because of the strong consumer desire for that option.231
Commentators suggested that once Wal-Mart made this decision, the
balance tipped in favor of "rBST-free" milk becoming the
conventional choice.23 2 Kroger food stores, along, with many others
nationwide, quickly followed suit by transitioning to certified rBSTfree milk supplies citing consumer demand as the reason for the
change. 233 Ultimately, these examples suggest consumers tend to find
ways to get the information they need about the foods they feed
themselves and their children, and the increasing availability of rBST
free products at conventional grocery and retail chains demonstrates
their preferences may decide the issue if not by government
regulation, than by market choice. Some suggest that one hundred
231. Wal-Mart Offers Private Label Milk Produced Without Artificial Growth
Hormone, WAL-MART, http://wvalmartstores.com/pressroom;news/8147.aspx (last
visited December 18, 2011) ("While the FDA has stated that milk from cows
treated with rbST poses no risk to human health, many Wal-Mart customers have
expressed a desire for milk choices. Today's announcement is evidence that WalMart is committed to keeping its product selection in line with what customers
expect to find when shopping its stores. 'We value our customers' opinions and
understand how important variety is in all aspects of the business,' said Pam Kohn,
senior vice president, general merchandise manager, Wal-Mart Stores, Inc. 'We've
listened to customers and are pleased that our suppliers are helping us offer Great
Value milk from cows that are not treated with rbST. ').
232. Janet MacFarand, WYal-Mart Move Tipping Point for Driving Monsanto's

Bovine Growth Hormone Off the Market, TORONTO GLOBE AND MAIL, Mar. 22,
2008, available athttp://www.organicconsumers.org/articles/article 11050.cfm.
233. Kroger, Kroger to Complete Transition to Certified rBST Free Milk By
Early 2008, THE KROGERCO.COM (Aug. 1, 2011) ""http://www.thekrogerco.com/
corpnews/corpnewsinfo pressreleases 08012007.htm (last visited September 30,
2011) ("For the past 10 years, Kroger has informed its raw milk suppliers that the
Company prefers milk from cows that have not been given rBST, based on
consumer preference.").; see e.g., Rick North, Consumer Demandfor rGBH-(rBST) FreeDairy Products, November 12, 2007, http://www.responsibletechnology.org/
docs/1 54.pdf (citing a number of business leaders who began supplying rBST free
dairy products because of increasing consumer demand).
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years ago, the pure foods issue was an important one in the election
of 1912.234 One hundred years later, the controversy surrounding the
Obamas' decision to plant an organic garden at the White House
suggests that perhaps it will be an issue that helps shape our nation's
politics and policies going forward.2 6

234. Anderson, supra note 16, at 31.
236. See e.g.. Crop

Life, Call to Action: A

Letter

Uriting

Campaign,

http://vww.croplife.com/article/601 (last visited January 1, 2012) (Urging citizens
to write a letter to Michelle Obama to encourage her to use "crop protection
products" keeping in mind the importance of conventional agriculture to our
national economy).

